Stockscreener 앱 받기
0.3449
1.03%
-0.0036
시간 외 거래:
.34
-0.0049
-1.42%
전일 마감가:
$0.3485
열려 있는:
$0.3477
하루 거래량:
7.89M
Relative Volume:
0.51
시가총액:
$80.95M
수익:
$48.47M
순이익/손실:
$-170.37M
주가수익비율:
-0.4599
EPS:
-0.7499
순현금흐름:
$-171.35M
1주 성능:
-8.61%
1개월 성능:
-0.46%
6개월 성능:
-85.51%
1년 성능:
-60.65%
1일 변동 폭
$0.3266
$0.35
1주일 범위
$0.3266
$0.3928
52주 변동 폭
$0.32
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3449 | 81.79M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Lost Money on Gossamer Bio, Inc. (GOSS)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Barchart.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ROSEN, A TOP RANKED RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman - ChartMill
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Price Today: Gossamer Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Oppor - GuruFocus
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lawsuit filed for Investors who lost money with shares of Gossamer Bio, Inc. (NASDAQ: GOSS) - openPR.com
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Gossamer Bio (NASDAQ: GOSS) outlines 2026 virtual annual meeting votes - Stock Titan
Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that - GlobeNewswire
GOSS DEADLINE TODAY: The Gross Law Firm Alerts Gossamer - GlobeNewswire
GOSS Forecast, Price Target & Analyst Ratings | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages zSpace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure - Intellectia AI
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman - ChartMill
Rosen Law Firm Urges Gossamer Bio, Inc. (NASDAQ: GOSS) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of - GlobeNewswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Hold" from Analysts - MarketBeat
How Mixed Trial Results And Balance Sheet Pressure Are Reframing The Gossamer Bio (GOSS) Story - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman - GlobeNewswire Inc.
Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial - TipRanks
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - ChartMill
GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS - ChartMill
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit -- The Gross Law Firm - PR Newswire
GOSS Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights - marketscreener.com
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with - GlobeNewswire
Gossamer Bio Inc stock (US38198T1034): Is its seralutinib pipeline strong enough to unlock biotech u - AD HOC NEWS
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is Gossamer Bio (GOSS) stock respecting key technical levels (Bullish Sentiment) 2026-04-18Macro Trends - Cổng thông tin điện tử tỉnh Tây Ninh
Gossamer Bio Inc stock (US38198T1034): Is seralutinib's Phase 3 push now the real test for breakthro - AD HOC NEWS
GOSS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Trial Claims: Levi & Korsinsky - TipRanks
GOSS Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% - GuruFocus
Robbins LLP Encourages GOSS Stockholders Who Lost Money Investing in Gossamer Bio, Inc. to Contact the Firm for Information About Leading the Class Action - The Malaysian Reserve
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):